Chronic Lymphocytic Leukemia | Specialty

The chronic lymphocytic leukemia condition center is a comprehensive resource for clinical news on chronic lymphocytic leukemia. Read more at OncLive.

Piecing Together the Proper BTK Usage in CLL

November 13th 2024

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

November 13th 2024

First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.

The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL

November 6th 2024

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

November 6th 2024

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

November 4th 2024

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

Dr Fisher on Mechanisms of Resistance with Covalent BTK Inhibitors in CLL

October 23rd 2024

David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors.

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21st 2024

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

October 16th 2024

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

October 12th 2024

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

Dr Jain on Treatment Considerations in the Frontline Management of CLL

October 9th 2024

Nitin Jain, MD, discusses current treatment options and considerations for the frontline management of CLL.

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

October 8th 2024

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Dr Dorritie on Acalabrutinib With/Without Obinutuzumab in Treatment-Naive CLL

September 27th 2024

Kathleen A. Dorritie, MD, discusses acalabrutinib with or without obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naïve CLL.

Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLL

September 11th 2024

Alexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

September 9th 2024

Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.

Dr Seymour on the Role of Mutational Profiling in CLL

September 6th 2024

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

September 6th 2024

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Clinical Pearls and Impacts to Practice from EHA 2024

September 5th 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Early Data Show High Responses With Zanubrutinib Plus Venetoclax in Treatment-Naive Del17p/TP53+ CLL/SLL

August 30th 2024

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.